Navigation Links
Syndax Pharmaceuticals to Present at Biotech Showcase 2011
Date:1/4/2011

WALTHAM, Mass., Jan. 4, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that Joanna Horobin, M.D., the company's president and CEO, will present at the Biotech Showcase 2011 on Tuesday, January 11, 2011 at 10:00 a.m. PT at the Parc 55 Wyndham hotel in San Francisco. Dr. Horobin's presentation will include the recently reported results from a randomized phase 2 study, which showed a four-month survival advantage when entinostat was added to erlotinib in patients with lung cancers expressing high levels of E-cadherin. In addition, she will review the ongoing phase 2 clinical programs for entinostat in breast, lung, colorectal cancer and hematologic malignancies.

The presentation will be available at Syndax's website, www.syndax.com.

About Syndax Syndax Pharmaceuticals, Inc. is a Waltham, MA-based, oncology-focused pharmaceutical company. Syndax is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens. Formed in 2005, the company's intellectual property is based on work from scientific founder Ronald Evans, Ph.D., recipient of the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator. Syndax has worldwide rights to develop and commercialize entinostat and is backed by top-tier Venture Capital firms: Domain Associates, MPM Capital, Avalon, Pappas and Forward Ventures. For more information please visit www.syndax.com. Contact Information E. Blair Schoeb Syndax Pharmaceuticals, Inc. Tel: 908-277-0386 bschoeb@syndax.com
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Syndax Pharmaceuticals Entinostat in Combination Shows Activity in Breast Cancer
2. Syndax Pharmaceuticals Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
3. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
4. Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
5. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
6. Amylin Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
7. VIDEO from Endo Pharmaceuticals Available on thenewsmarket.com: FDA Approves New Treatment for Low Testosterone
8. Lotus Pharmaceuticals Announces Approval of Reverse Stock Split
9. Cumberland Pharmaceuticals Announces Voluntary Recall of Acetadote® Vials
10. Endo Pharmaceuticals Receives FDA Approval for FORTESTA™ (Testosterone) Gel as a Class III Product for Topical Use for Men with Low Testosterone
11. Reportlinker Adds E7: The Outlook for Pharmaceuticals to 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today announced that it will release third-quarter ... October 26, 2017, and will follow with a conference ... 9:00 a.m. Eastern Time. To participate on the call, ... ID is 94093362. ...
(Date:10/10/2017)... 2017  NDS received FDA 510(k) clearance in May 2017 for ... stand specifically designed for endoscopy environments. An innovative secondary monitor solution, ... solution to support the improvement of patient outcomes, procedural efficiency, and ... ... ...
(Date:10/4/2017)... to the Centers for Disease Control and Prevention (CDC), influenza vaccination ... is helping communities across Massachusetts , Connecticut ... flu shots through the end of the month. *Some exclusions ... ... shot is by the end of October, according to the Centers for ...
Breaking Medicine Technology:
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical ... Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. ... honor of Morris F. Collen, a pioneer in the field of medical informatics, this ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
(Date:10/12/2017)... ... , ... Health Literacy Innovations (HLI), creator of the Health ... Cancer Patient Education Network (CPEN), an independent professional organization that shares best practices ... , As CPEN’s strategic partner, HLI will help support CPEN members by ...
Breaking Medicine News(10 mins):